GlassScriptPhysician profile
Alexander J Vanderby
NPI 1083061246
$4,662.39
in general payments reported to CMS, 2019-2025
30 companies · $1,004 in 2025
The $1,004 reported for 2025 was more than what 86% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $478 · 2020: $364 · 2021: $438 · 2022: $712 · 2023: $956 · 2024: $710 · 2025: $1,004.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,670.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,670.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $932.74 | 2021-2025 | Dalvance, Teflaro |
| Pfizer INC. | $680.34 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $329.92 | 2021-2025 | Camzyos, Eliquis |
| Amgen INC. | $293.20 | 2019-2023 | Repatha |
| Novartis Pharmaceuticals Corporation | $277.10 | 2019-2025 | |
| Mylan Specialty L.P. | $267.75 | 2019-2024 | Yupelri |
| Viatris Specialty LLC | $201.89 | 2025 | Yupelri |
| Astrazeneca Pharmaceuticals LP | $201.31 | 2020-2024 | Andexxa, Farxiga |
| Janssen Pharmaceuticals, INC | $147.43 | 2019-2024 | Xarelto |
| Shionogi INC | $140.96 | 2023-2024 | Fetroja |
| Phathom Pharmaceuticals, INC. | $119.55 | 2024 | Voquezna |
| Alexion Pharmaceuticals, INC. | $118.11 | 2022-2025 | Ultomiris, Soliris |
| Stryker Corporation | $111.33 | 2025 | Flowtriever, Clottriever Bold Catheter |
| Gilead Sciences, INC. | $106.60 | 2022-2023 | Veklury |
| Viiv Healthcare Company | $99.84 | 2019 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $89.10 | 2021-2025 | Recarbrio, Dificid, Zerbaxa |
| Novo Nordisk INC | $78.14 | 2020 | |
| Mallinckrodt Hospital Products INC. | $76.05 | 2024-2025 | Terlivaz |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $67.44 | 2024-2025 | Lifevest |
| Chiesi USA, INC. | $60.69 | 2019-2024 | Cleviprex |
| Vertex Pharmaceuticals Incorporated | $49.98 | 2025 | |
| Smith+Nephew, INC. | $41.27 | 2019-2023 | Collagenase Santyl |
| Cvrx, INC. | $31.73 | 2025 | Barostim Neo System |
| Inari Medical, INC. | $29.71 | 2023 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Actelion Pharmaceuticals US, INC. | $26.88 | 2025 | Uptravi |
| Global Blood Therapeutics, INC. | $19.97 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $18.20 | 2024 | Rexulti, Nuedexta |
| Vifor Pharma, INC. | $15.38 | 2020 | |
| Melinta Therapeutics, LLC | $15.15 | 2025 | Rezzayo |
| Tris Pharma INC | $14.63 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alexander Vanderby listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.